Table 1.
Patient characteristics at baseline
| Case number | 78 patients |
|---|---|
| Sex (male/female) | 50/28 |
| Age (years) | 70 (20–87) |
| APACHE II score | 24 (3–38) |
| SOFA score | 11 (0–19) |
| MAP before the PMX treatment (mmHg) | 64 (40–104) |
| CVP before the PMX treatment (mmHg) | 15 (12–22) |
| Creatinine before the PMX treatment (mg/dl) | 1.42 (0.41–10.24) |
| Endotoxin level before the PMX treatment (pg/mL) | 11.3 (0.8–1925) |
| Lactate level before the PMX treatment (mmol/L) | 3.7 (1.0–23.0) |
| Patients with diabetes mellitus | 24 |
| Patients received corticosteroid therapy | 13 |
| The times of PMX therapy | 1 (1–6) |
| Total PMX treatment time (min) | 1456 (80–18,100) |
| Suspected causative microorganisms | |
| GNR | 41 |
| GPC | 12 |
| GPR | 2 |
| Unknown origin | 23 |
| Infection site | |
| Abdomen | 27 |
| Bloodstream | 15 |
| Lung | 10 |
| Urinary tract | 6 |
| Others (unknown origin) | 20 |
Data are presented as number of cases or median (range). MAP mean arterial pressure, CVP central venous pressure, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, PMX polymyxin B-immobilized fiber column hemoperfusion, GNR Gram-negative rods, GPC Gram-positive cocci, GPR Gram-positive rods.